Paul Revill

Correction to: Nature Communications https://doi.org/10.1038/s41467-025-60752-y, published online 1 July 2025 In the version of this article initially published, there was an error in the values shown in Table 3 for people with HIV who have ever taken lenacapavir + cabotegravir, where the percentage of people with virologic failure was originally listed as “7% (1% − 29%) 10% (9% − 10%)”; the table is now corrected to list “0% (0% − 0%) 0% (0% − 0%)” in the HTML and PDF versions of the article.

The authors have declared no competing interest. Yes I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Thanzi La Onse project received ethical approval from College of Medicine Malawi Research Ethics Committee (COMREC, P.10/19/2820) in Malawi.